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Abstract
Objective—Vitamin D has been linked to anti-Müllerian hormone levels, suggesting a possible 
association with greater ovarian reserve, but large population-based studies are lacking. Our 
objective was to explore the association between vitamin D and FSH in premenopausal women.
Methods—The Uterine Fibroid Study (1996 – 1999) enrolled randomly-selected 30 – 49 year-
old members of a Washington D. C. health plan (N=1430). Women provided a blood and urine 
sample in addition to questionnaire data. The vitamin D metabolite 25-hydroxyvitamin D 
(25(OH)D) was measured in stored plasma samples. Urinary FSH (mIU/mg creatinine) was 
measured with an immunofluorometric assay. To obtain baseline measures, this investigation was 
limited to urine samples collected in the first 5 days of the menstrual cycle or 5 days prior to 
menses onset. Additionally, post-menopausal women and women using oral contraceptives were 
excluded, leaving 527 women in our analysis. FSH was creatinine-adjusted, normalized by log-
transformation, and then modeled with multivariable linear regression.
Results—The median 25(OH)D level was 12 ng/mL, with approximately 75% of participants 
below the recommended level of 20 ng/mL. FSH and 25(OH)D were inversely related. For an 
increase of 10 ng/mL in 25(OH)D, urinary FSH decreased 14% (95% Confidence Interval: −23%, 
−5%), p=0.003.
Conclusions—Vitamin D is inversely related to FSH. This is consistent with literature relating 
low vitamin D with lower anti-Müllerian hormone. Prospective studies should investigate whether 
low levels of vitamin D contribute to decreased ovarian reserve.
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Vitamin D is known for its role in bone health1, but its role in reproduction is an active area 
of investigation2–4. Vitamin D receptors are expressed in the ovary, placenta, and the 
uterus2–4. Lower Vitamin D has been related to premenstrual syndrome, uterine fibroids5, 
dysmenorrhea and early menarche4.
Vitamin D deficiency has been associated with dramatically reduced fertility in both rats and 
mice when diet interventions reduce levels2,6. Female knock-out mice with no functional 
vitamin D receptor showed hypergonadotropic hypogonadism, a condition characterized by 
high levels of follicle stimulating hormone (FSH) and low levels of estrogen. Low levels of 
25(OH)D have also been associated with primary ovarian insufficiency in humans7. Data 
from prostate cancer cells show that the AMH promoter region contains a vitamin D 
response element8.
Given these studies, we hypothesized that vitamin D may be important for maintaining the 
health of primordial follicles, or limiting excess recruitment from the primordial follicle 
pool, and thus, depletion of ovarian reserve. Early follicular-phase follicle stimulating 
hormone (FSH), which can be measured in blood or urine, is a biomarker of ovarian reserve 
which rises across the late reproductive lifespan and is inversely related to AMH9. We 
theorized that vitamin D, measured as serum 25-hydroxyvitamin D (25(OH)D), would be 
inversely correlated with FSH in late reproductive-age women.
Methods
Study sample
The National Institute of Environmental Health Sciences (NIEHS) Uterine Fibroid Study, 
1996 – 1999, enrolled participants identified from a large health plan in Washington, 
DC5,10,11. In brief, randomly selected health plan members between the ages of 30 and 49 
were contacted and 80% of those eligible participated (N=1430). For this analysis, only 
women who were pre-menopausal and not currently using oral contraceptives were included 
(N=1148) (Figure 1). Women were invited to the primary care site for an in-person study 
visit that included a blood draw. Blood samples were processed and stored at −80C.
Vitamin D measurement
Vitamin D status was ascertained through the measurement of the circulating metabolite 25-
hydroxyvitamin D (25(OH)D) in stored plasma samples. 25(OH)D is a widely accepted 
biomarker for vitamin D12. 25(OH)D was measured by radioimmunoassay13 at a laboratory 
that has been certified by the international Vitamin D External Quality Assessment Scheme 
for the past 12 years (intra- and interassay coefficients of variation were 7.6 and 10.6%5). 
The antibody was co-specific for both 25(OH)D2 and 25(OH)D3. One hundred and fifty-five 
women were missing a 25(OH)D measurement, most of whom had no available blood 
sample. This left 993 available for analysis of vitamin D.
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We measured FSH in urine. Urinary FSH is highly correlated with serum FSH (r=0.9, 
p<0.0114) and it is much easier to obtain urine samples timed to the menstrual cycle than 
timed blood samples because women can collect their own urine at home. The first 
approximately 600 pre-menopausal women enrolled in the study were asked to collect first-
morning urine samples on the 2nd and 3rd days of their menstrual cycle. Samples were 
refrigerated and then shipped overnight in a cold-storage kit with freezer packs (provided by 
the study) to the study site in North Carolina. Upon arrival, equal aliquots from each day 
were pooled. Women who were not asked to collect menstrually-timed urine samples instead 
collected a first-morning sample on the day of their study clinic visit. Women who attended 
the clinic visit without bringing a first-morning urine sample were asked to provide a spot 
sample. Glycerol was added to all urine samples, which were then stored at −80C. Menstrual 
cycle day was reported at the clinic visit and in menstrual diary data collected during the 
menstrual cycle following the visit.
Urinary FSH (mIU/mg creatinine) was measured in duplicate using a noncompetitive, time-
resolved immunofluorometric assay15. Creatinine was measured spectrophotometrically. 
Within- and between-assay percent coefficients of variation were 3.1% and 1.1% for FSH 
and 2.2% and 4.2% for creatinine. To avoid the mid-cycle peak of FSH we used FSH 
information for women whose urine sample was collected during the first 5 days of the 
menstrual cycle or 5 days prior to the onset of the subsequent menses (N=527) (Figure 1). 
Of these 527 women, 436 women used the urine collection kit on days 2 and 3 of the 
menstrual cycle to collect two first-morning urine samples that were subsequently pooled. 
Of the remaining women, single first-morning urine specimens were provided by 73 women 
while 16 provided a spot urine sample at their study visit. Prior to statistical analysis 
creatinine-adjusted FSH was log-transformed to achieve normality.
Covariates
Data on covariates were collected through a self-administered questionnaire and a telephone 
interview. Body weight was measured at the clinic visit. Potential confounders considered 
included: age, education, race, body mass index (BMI), alcohol intake, cigarette smoking, 
physical activity, age at menarche, gravidity, mother’s age at menopause, menstrual cycle 
day of urine collection and season of blood draw (winter vs. other).
Statistical analysis
The association between 25(OH)D and the natural log of FSH was analyzed through 
multivariable linear regression. Regression coefficients from this model were first multiplied 
by 10 corresponding to a 10 ng/mL increase in 25(OH)D, exponentiated, and then multiplied 
by 100 and are presented as the percent change in FSH.
The analysis of FSH was adjusted at first for only age, race, and cycle day of urine 
collection, “Model 1”. A second, fully-adjusted model, “Model 2,” included the previous 
variables and BMI, current smoking, and season of blood draw. Adjustment for education, 
alcohol intake, gravidity, and participant’s mother’s age at menopause did not alter the 
results and were excluded from the final model. Sensitivity analyses were performed to 
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compare the association among women who collected urine only on days two or three of the 
menstrual cycle (N=436) with the sample as a whole (N=527) (Figure 1). Of the 527 women 
in the complete sample, 7 women reported having had one ovary removed (one woman was 
missing this information) and 11 self-reported a diagnosis of polycystic ovary syndrome 
(PCOS). In a sensitivity analysis, results were unchanged after excluding these women.
Results
Participants were between the ages 35 and 51 at the time of the blood draw, with a mean and 
median age of 42 years (Table 1). The majority of women were of black race, a little over 
half had at least a college degree, and almost 80% had been pregnant at least once. 
Approximately 60% of the women were overweight or obese, about 80% of the women were 
non-smokers and about half of the women drank no more than one drink per week on 
average. The mean 25(OH)D level was 14.3 ng/mL (standard error: 0.36), with a median of 
12.3 ng/mL (interquartile range: 7.8, 20.1 ng/mL) (Figure 2). Approximately 75% of the 
women had a 25(OH)D level below the IOM recommendation of 20 ng/mL for “adequate” 
vitamin D.
In Model 1, there was a highly significant inverse association between 25(OH)D and FSH 
levels, with a 10 ng/mL decrease in 25(OH)D associated with an approximate 10% increase 
in FSH (Table 2, Figure 3). Adjustment for all covariates increased the estimate to 14% 
(Table 2). Limiting the sample to women who collected pooled urine samples only on days 
1, 2, or 3 of the menstrual cycle did not substantially alter these associations (Table 2). 
Excluding women with diabetes (N=17) also did not alter these associations (data not 
shown). The adjusted association was slightly stronger for women less than 40 years of age 
(Percent change (CI): −19% (−33, −6), p=0.007) compared with women at least 40 years of 
age (Percent change (CI): −12% (−24, −.1), p=0.05). Ninety percent of black women had a 
25(OH)D below 20 ng/mL compared with 50% of the white women. The adjusted 
association of 25(OH)D and FSH was stronger among black women (Percent change (CI): 
−18% (−31, −4), p=0.01), compared with White women (Percent change (CI): −9% (−23, 4), 
p=0.18), although a test of the multiplicative interaction term between race and 25(OH)D in 
the model was not significant (p=0.30).
Discussion
Lower plasma 25(OH)D was associated with higher FSH levels, a biomarker of ovarian 
reserve, which suggests a decrease in primordial follicles and possible acceleration towards 
menopause. Previous studies examining the relationship between Vitamin D and ovarian 
reserve have measured AMH levels. AMH, which is produced by the granulosa cells of 
preantral and early antral follicles, appears to be an important regulator of follicle 
development16. Serum levels of AMH have also been shown to be an indicator of ovarian 
reserve9,17. Human studies have reported a positive correlation between serum 25-
hydroxyvitamin D (25(OH)D) and AMH18,19. One of these studies involved a unique cohort 
of women participating in an HIV-infection study and reported that the association was 
limited to women over 40 years of age19. The other publication describes an intervention 
study in New Zealand that included only 33 women18. The authors report that AMH varied 
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across seasons and that supplementation with cholecalciferol (vitamin D3) prevented 
seasonal AMH changes18. This would suggest that vitamin D may affect the preantral or 
antral follicle pool, which can fluctuate in size, but not the primordial follicles.
Age of menopause has been associated with sun exposure in two studies from Turkish 
populations20,21 and in a study of Italian nuns22. In all three studies, women whose lifelong 
sun exposure was estimated to be low (due to sun avoidance, covered dressing, or a lack of 
outdoor activity) had an earlier age at menopause. It is possible that vitamin D is a 
mechanism underlying this association.
The ability to produce vitamin D in the skin is dependent upon skin pigmentation,23 and 
pigmentation varies with race/ethnicity. In the United States, vitamin D levels are 
correspondingly lower among African-Americans compared with non-Hispanic Whites24. 
However, ethnic groups differ on many factors, and the data on age at menopause and race/
ethnicity are mixed25–30.
The mechanism by which vitamin D may affect ovarian reserve is unknown. Ovarian 
reserve is susceptible to toxicants such as tobacco smoke31. The smoking effect on ovarian 
reserve seems to be most evident during the perimenopausal years, as evidenced by the fact 
that only current smoking during the late reproductive and peri-menopause appears to affect 
age at menopause32,33. In contrast, the current study found that the inverse relationship 
between FSH and vitamin D appeared to be somewhat stronger in the younger participants. 
This suggests the possibility that chronic low vitamin D levels might have a more 
continuous adverse effect on ovarian reserve.
This analysis incorporates a population-based sample and a larger sample size (N=527) 
compared with the two previous AMH studies (N=388 and 33). This study is also 
strengthened by its use of a plasma 25(OH)D measure performed by a well-recognized 
expert and developer of the assay12. The lab has participated in and been certified by the 
DEQAS survey for the past 12 years. The intra and inter assay variation is <10 % based on 
laboratory controls. Most of the women in this study had inadequate 25(OH)D levels based 
on the IOM standard. This improves the power of the study to detect an association between 
low vitamin D and FSH, although it may also limit the generalizability of our results to more 
vitamin D replete populations. Similarly, most of this population was of Black race and over 
35 years of age which limits our generalizability to women of other races and younger 
women. This study included thorough collection of menstrual cycle information which 
minimizes misclassification of the FSH measure. FSH was measured in urine rather than in 
blood, which may limit its clinical interpretation. However, the correlation between blood 
and urine measurements is high14. AMH was not measured in this population, so we were 
unable to assess the association between 25(OH)D and AMH. While all the women in our 
analysis reported being premenopausal, some of them may have been perimenopausal, and 
levels of both 25(OH)D and FSH may change during menopause. However, when we 
limited our analysis to women under 40 the association between 25(OH)D and FSH was 
stronger, suggesting a minimal influence of perimenopause on our results.
Jukic et al. Page 5























Vitamin D was inversely related to urinary FSH levels in a population of older 
premenopausal women. This suggests vitamin D may influence ovarian reserve and as such, 
may have implications for fecundability in older women. The mechanism through which 
vitamin D may affect FSH is unknown, and warrants further investigation.
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Flowchart showing the number of women in the Uterine Fibroid Study included in the 
analysis of 25(OH)D and urinary FSH level during the early follicular or late luteal phase of 
the menstrual cycle.
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Distribution of plasma 25-hydroxyvitamin D status among women with an early follicular or 
late luteal measure of urinary FSH (n=527). A vertical line is drawn at 20 ng/mL, the IOM 
recommendation for adequate 25(OH)D.
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Results of the unadjusted linear regression model of 25(OH)D predicting the natural log of 
FSH (solid line) (and predicted 95% confidence bands (dotted lines)) among 436 women 
who collected urine on cycle days 2 and 3 of the menstrual cycle. The y-axis tick marks are 
spaced on the natural log scale, but labeled on the absolute scale, for ease of interpretation.
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Table 1
Characteristics of participants in the Uterine Fibroid Study who were included in the analysis of 25(OH)D and 
FSH (N = 527), Washington D.C. (1996 – 1999).
Mean (SE)
FSH, mIU/mg CRT (mean (SE)) 11.5 (0.36)
N (%)
Age
  35 – 39 160 (30)
  40 – 44 199 (38)
  45 – 51 168 (32)
Race
  White 197 (37)
  Black 298 (57)
  Other 32 (6)
Education
  High school graduate or less 63 (12)
  Some college or technical school 176 (33)
  College degree or some graduate school 141 (27)
  Post-graduate degree 145 (28)
  Missing 2 (0.4)
Gravidity
  0 109 (21)
  1, 2 173 (33)
  ≥ 3 245 (46)
Body mass index
  < 25 kg/m2 214 (41)
  25 – < 30 144 (27)
  30 – <40 129 (24)
  ≥40 40 (8)
Current Smoker 103 (20)
Alcohol (drinks per week)
  0 106 (20)
  > 0 – 1 157 (30)
  > 1 – 7 172 (33)
  > 7 65 (12)
  Missing 27 (5)
Age at menarche
  <11 years 45 (9)
  11 – 14 428 (81)
  >14 years 53 (10)
  Missing 1 (0.2)
Mother’s age at menopause
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Mean (SE)
  19 – 49 150 (28)
  50 – 65 127 (24)
  Missing 193 (37)
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